Treatment of primary palmar hyperhidrosis

Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202006915898923

Enrollment

Registered

2020-06-22

Start date

2020-05-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

topical aluminum chloride hexahydrate

Oral Oxybutynin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study include patients with primary palmar hyperhidrosis aged nine years or more with Hyperhidrosis Disease Severity Scale (HDSS) of at least 2 and agree to keep on follow-up.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women, hypersensitive to any of the active ingredients or have a history of hypersensitivity, known closed angle glaucoma or known prostatic disorders, intestinal obstruction, toxic megacolon, intestinal atony, severe ulcerative colitis, and myasthenia.

Design outcomes

Primary

Measure	Time frame
HDSS	—

Secondary

Measure	Time frame
Clinical grading	—

Countries

Egypt

Contacts

Public ContactAbdelHady ElGilany

professor of public health and community medicine Faculty of medicine Mansoura university

ahgilany@gmail.com00201060714481

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026